Related Experiment Video

Updated: Mar 28, 2026

Author Spotlight: Advancing Hepatic Fibrosis Diagnosis Using Magnetic Resonance Elastography and AI
06:09

Author Spotlight: Advancing Hepatic Fibrosis Diagnosis Using Magnetic Resonance Elastography and AI

Published on: July 21, 2023

2.1K

Assessment of liver fibrosis using pharmacokinetic parameters of dynamic contrast-enhanced magnetic resonance imaging

Zhiming Li1, Jihong Sun1, Lumin Chen1

  • 1Department of Radiology, Sir Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.

Journal of Magnetic Resonance Imaging : JMRI
|December 29, 2015
PubMed
Abstract

Insights

Dynamic contrast-enhanced MRI (DCE-MRI) pharmacokinetic parameters, particularly K(trans), effectively diagnose and stage liver fibrosis in rabbits. This imaging technique shows promise for non-invasively assessing liver disease progression.

Area of Science:

  • Radiology
  • Medical Imaging
  • Pharmacokinetics

Background:

  • Liver fibrosis is a significant health concern.
  • Accurate staging of liver fibrosis is crucial for patient management.
  • Non-invasive diagnostic methods are highly desirable.

Purpose of the Study:

  • To evaluate dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) pharmacokinetic parameters for diagnosing and staging liver fibrosis in rabbits.
  • To assess the diagnostic performance of DCE-MRI parameters in differentiating fibrosis stages.

Main Methods:

  • DCE-MRI was performed on rabbits with CCl4-induced liver fibrosis and a control group.
  • Fibrosis was staged using the METAVIR system (F0, F1-2, F3-4).
  • Pharmacokinetic parameters (K(trans), kep, Ve, vp) were measured using a dual-input extended Tofts model.

Main Results:

  • K(trans) and Ve decreased with increasing fibrosis stage.
  • K(trans) showed significant differences between control and all fibrosis groups (P < 0.001).
  • K(trans) demonstrated high diagnostic performance (AUROCs > 0.887) for differentiating fibrosis stages.

Conclusions:

  • K(trans) is an excellent DCE-MRI pharmacokinetic parameter for differentiating normal livers from fibrotic livers.
  • DCE-MRI parameters, especially K(trans), can effectively stage liver fibrosis in rabbits.
  • This study highlights the potential of DCE-MRI for non-invasive liver fibrosis assessment.
Keywords:
dynamic contrast-enhanced magnetic resonance imagingliver fibrosispharmacokinetic parameter

More Related Videos

Author Spotlight: A Non-Invasive Tool to Assess and Differentiate Fat Patterns in Liver Using 3D Dixon MRI05:37

Author Spotlight: A Non-Invasive Tool to Assess and Differentiate Fat Patterns in Liver Using 3D Dixon MRI

Published on: October 20, 2023

2.4K
Measurement of Liver Stiffness Using Atomic Force Microscopy Coupled with Polarization Microscopy10:10

Measurement of Liver Stiffness Using Atomic Force Microscopy Coupled with Polarization Microscopy

Published on: July 20, 2022

4.9K

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
256
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
334
Ultrasound II: Endoscopic Ultrasound and FibroScan01:25

Ultrasound II: Endoscopic Ultrasound and FibroScan

Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
1.1K
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
296